Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 13 February 1998:
Vol. 279. no. 5353, pp. 976 - 977
DOI: 10.1126/science.279.5353.976
Prev | Table of Contents | Next

News & Comment

BIOMEDICAL FUNDING:
FDA Scientists Resist Cuts in In-House Research Positions

Bruce Agnew

Nearly one-third of the research job slots at the Food and Drug Administration's (FDA's) Center for Biologics Evaluation and Research (CBER), which combines research with regulation, are slated to disappear over the next 2 years because the FDA has promised not to draw on pharmaceutical industry "user fees" to fund them. Faced with that dire prospect, some CBER scientists are trying to recruit support in Congress, and others are appealing to outside scientists for help. At stake, the CBER scientists say, is the safe and efficient regulation of products such as vaccines and cell-derived proteins, the biological therapeutics that are at the heart of the biotech revolution.

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)